id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0575-0028,FDA,FDA-2013-D-0575,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics,Notice,30 Day Proposed Information Collection,2013-11-07T05:00:00Z,2013,11,2013-11-07T05:00:00Z,2013-12-10T04:59:59Z,2016-11-04T15:06:21Z,2013-26695,0,0,090000648147285f
FDA-2013-D-0575-0002,FDA,FDA-2013-D-0575,Draft Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics,Other,Guidance,2013-06-26T04:00:00Z,2013,6,2013-06-26T04:00:00Z,,2024-11-12T05:18:57Z,,1,0,09000064813419e9
FDA-2013-D-0575-0001,FDA,FDA-2013-D-0575,Draft Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics; Availability,Notice,Notice of Availability,2013-06-26T04:00:00Z,2013,6,2013-06-26T04:00:00Z,2013-08-27T03:59:59Z,2013-09-05T01:03:53Z,2013-15250,0,0,090000648134164a